Peptide User Survey 2026: Sourcing Data
In May 2026, Peptime (@ItsPeptime on X) posted results from a self-selected online survey of 1,000+ peptide users. The dataset is one of the largest non-clinical reads on how peptides are actually being sourced, paid for, and combined in 2026. Below: every finding rebuilt with original tables, our analysis, and the limitations to read it with.
Update History ▾
May 19, 2026: Initial publication. All eight findings rebuilt with original tables; primary source verified against the Peptidepedia post on May 18, 2026.
The Peptime 2026 survey is not a clinical study, but at 1,000+ respondents it is one of the largest community reads on how peptides are actually being bought and used. Two structural patterns stand out. Sourcing is dominated by the gray market — 70% of respondents buy from suppliers selling under a “Research Use Only” label, and most are explicit that they know they are operating in a legal gray zone. Spending is concentrated and high — the median user reports $100–$249 a month, but roughly 11% report $1,000+ a month, which puts annual spend above $12,000. All of it is self-reported by engaged users; none of it is peer-reviewed.
- 70% source from “Research Use Only” suppliers; only 11% go through a local doctor or telehealth provider.
- 68% describe their own use as a “legal gray area”; another 14% call it “probably illegal.”
- Median spend is $100–$249/month; 11% report $1,000+/month (≈ $12,000+/year).
- Tech is the largest single industry cohort — 75% reported use rate, well ahead of finance (46%) and consulting (45%).
- Stacks beat singles on self-rated effectiveness — 3.2/4 for 3+ peptide stacks vs 2.0/4 for single-peptide use.
- 25–34 is the buying cohort — 75% reported use rate, more than triple the 18–24 cohort.
- 68% rate their experience as “very effective” or “life-changing” — self-report only, no control, heavy selection bias.
About the Survey
A few months before May 2026, Peptime — an X account (@ItsPeptime) that describes itself as a US peptide shop — ran an opt-in survey on its own website. Its May 18, 2026 post reported 1,000+ anonymous responses and summarised findings on sourcing channel, monthly spend, industry, age, stacking behaviour, and self-rated outcomes.
This is not a clinical study. It is a self-selected online survey of people who already had enough interest in peptides to find a peptide seller’s website and finish the questionnaire. That has predictable consequences for the data:
- Selection bias is heavy. Respondents skew toward engaged, current users.
- All outcomes are self-reported. There are no verified labs, biomarkers, or controls.
- Heavy users are likely over-represented. The casual or one-time user is under-counted.
Read with those caveats in mind, the survey is best treated as a market-state snapshot of the engaged peptide user base in 2026 — not as evidence about whether or how well any specific compound works in a general population.
Finding 1: Grey Market Peptides Dominate — 70% of Users Source From RUO Suppliers
The clearest result in the dataset is also the most consequential. Seven in ten respondents reported buying grey market peptides — product sold under a “Research Use Only” label rather than through a prescription pathway. Fewer than one in five users went through any kind of doctor. The gray market is not a transition state in this data; it is the primary distribution channel.
| Source channel | Share of respondents | What it means |
|---|---|---|
| “Research Use Only” supplier | 70% | Material sold for in-vitro research, not for human use |
| Overseas clinic | 12% | Prescription written abroad, product imported |
| Local doctor or telehealth | 11% | Domestic prescription pathway |
| Friends or informal channels | 9% | Unverified provenance and storage chain |
Awareness of the legal posture is high. 68% of respondents called their own use a “legal gray area,” another 14% described it as “probably illegal,” and only 18% believed what they were doing was clearly legal. The framing matters: the gray market is not a transient state on the way to regulation in this sample. It is the dominant distribution channel and users are explicit that they understand what that means. For research-grade buyers, the consequence is that supplier verification — third-party HPLC, batch COAs, cold-chain handling, and a real address — carries more weight than nominal compliance language. Our COA library exists for exactly this reason.
Finding 2: Annual Spend Reaches $12,000+
Spending is concentrated. The median respondent spent $100–$249 a month — consistent with a single GLP-1 product cycled monthly — but the top of the distribution is steep. Roughly 11% reported $1,000+ a month, which annualises to $12,000 or more per user. That puts the heavy-user cohort in territory normally reserved for private school tuition or a paid-off car payment.
| Monthly spend tier | Share of respondents | Approx. annualised |
|---|---|---|
| Under $100 | (remainder of sample) | < $1,200 |
| $100 – $249 (median band) | Largest single tier | $1,200 – $3,000 |
| $500 – $999 | 18% | $6,000 – $12,000 |
| $1,000+ | 11% | $12,000+ |
The takeaway from the survey is structural: this is not a casual hobbyist category. A meaningful slice of users are spending mid-five figures a year, which has implications for how seriously suppliers need to take cold-chain integrity, batch documentation, and customer support.
Finding 3: Tech Leads Industry Adoption
The industry breakdown reads like a chart of who has both disposable income and an information-dense relationship with their own bodies. Tech sits at the top by a clear margin; healthcare and biotech follow, which suggests a domain-knowledge effect; construction lands surprisingly high, which is harder to explain from the public data alone.
| Industry | Reported use rate | Read |
|---|---|---|
| Technology | 75% | Highest single cohort; high income, high biohacking saturation |
| Healthcare / biotech | 59% | Domain familiarity lowers the activation barrier |
| Construction | 55% | Physical-recovery use case is plausible but unverified |
| Finance | 46% | Disposable income, less category fluency |
| Consulting | 45% | Similar profile to finance |
The number to be careful with here is the construction figure. The survey reached users through Peptime’s own audience, which means the industry mix is shaped by who already reads peptide content — not by the broader workforce. A 55% use rate in a small subset of construction-industry respondents who already found a peptide site is not the same as a 55% use rate among construction workers generally.
Finding 4: Stacks Beat Singles on Self-Rated Effectiveness
Respondents using a single peptide rated their experience at 2.0/4 (“somewhat effective”). Respondents stacking three or more compounds rated theirs at 3.2/4 (“life-changing”). That is a 60% jump on a self-rating scale, and it is the survey’s most actionable behavioural pattern.
Two readings are possible and both probably matter. Stack composition genuinely produces better self-perceived results — users layering, say, a GLP-1 with a recovery peptide and a sleep peptide are addressing more pain points and report a larger total effect. Or the higher self-rating is partly a commitment effect — people who have invested in a three-product stack are more invested in believing it worked. Both can be true at once. The survey can’t separate them.
What it does tell suppliers and content creators is that the question buyers are actually trying to answer is rarely “what does this single peptide do.” It is “what do I combine it with.” A single-product framing leaves most of the user’s real decision unaddressed.
Finding 5: 25–34 Is the Buying Cohort
The use-rate jump between the youngest and the second-youngest cohort is the largest single gap in the dataset. Gen Z reads about peptides; millennials buy them.
| Age cohort | Reported use rate | Read |
|---|---|---|
| 18 – 24 | 22% | Information audience; not yet conversion audience |
| 25 – 34 | 75% | Largest single jump in the dataset |
The pattern is consistent with what disposable-income gating looks like in any premium consumer category. Peptides cost real money on a monthly basis, and 25–34 is the cohort where that money first becomes available. For content and SEO planning, this argues for two layers: informational content that serves the 18–24 reader (and earns the citation), and conversion-oriented content that serves the 25–34 buyer when they are ready.
Finding 6: 68% Rate Their Experience as “Very Effective” or Better
Self-rated outcomes are the most caveat-heavy number in the survey, and we are surfacing the caveat first: these respondents took a peptide quiz on a peptide seller’s website. They are not a representative sample of anyone, and the rating reflects how engaged users feel about their use, not what any peptide actually does in a controlled setting.
| Self-rating | Share of respondents |
|---|---|
| Life-changing | 26% |
| Very effective | 42% |
| Somewhat effective | 23% |
| Not very effective | 9% |
Roughly 68% sit at “very effective” or above. That number is real for the people answering, and it explains the high re-up rate the spending data implies. What it is not is evidence that peptides produce those outcomes in a general population, in any specific protocol, or for any specific indication. Anyone reading the survey for buying signals should weight this column the lightest of the six.
What the Data Tells Us About the 2026 Peptide Market
Two structural reads come out of the dataset, regardless of where the noise sits.
The gray market is structural, not transitional. 70% of demand is being filled by suppliers selling under a research-use label. That share is too large to be a regulatory waiting room. It is the dominant channel and it is likely to stay dominant until either the legal framework changes or a regulated equivalent reaches the same price point and convenience. For buyers, the practical consequence is that supplier choice matters more than category choice — verification, COA documentation, and handling discipline are the deciding factors at the point of purchase. See our how we verify and dispatch retatrutide in Dubai for what that verification looks like in practice.
Stacks are the unit of decision, not single compounds. Single-peptide content under-serves the buyer’s actual question. The 3+ peptide stack rating of 3.2/4 vs the single-peptide rating of 2.0/4 is the loudest behavioural signal in the survey. Coverage of any peptide that does not address what it stacks with is leaving most of the user’s decision unanswered.
Limitations of a Self-Selected Online Survey
Every number in this article should be read against the same set of constraints. We are surfacing them in one place rather than burying them in footnotes.
- Self-selected sample. Respondents found Peptime’s website, opted in, and finished a quiz. They are not a representative slice of any defined population.
- Self-reported responses. No lab verification, no biomarker corroboration, no third-party check on what was actually used or for how long.
- No control group. Comparison to non-users or to placebo is not possible from the data.
- Heavy users over-represented. People who spend more time on peptide content are more likely to complete a peptide quiz. The casual or one-time user is systematically under-counted.
- A seller hosted it. Peptime describes itself on X as a US peptide shop. A survey hosted by a seller reaches that seller’s audience; a survey hosted on a general-health site would likely produce different numbers.
- Recall and framing effects. Monthly spend, stacking effectiveness, and reasons-for-use all depend on how respondents remember and frame their own behaviour.
None of these dismiss the data. They define what it is for. The survey is a directional read on engaged-user behaviour, not a clinical or market-share study. We treat it accordingly.
A Note on Research Use Only
Remy Research products are supplied for in-vitro laboratory research only. They are not intended for human or veterinary use, diagnosis, treatment, prevention, or cure of any condition. The survey data summarised here describes how respondents reported behaving and feeling; it is not guidance to act on. See our research standards for how we document and verify product on our side.
Our Research Standards
This article summarises a third-party community survey and adds our own analysis, original tables, and limitations. The primary source — the May 18, 2026 Peptime (@ItsPeptime) post on X — was re-checked on October 7, 2026. All numerical claims are direct from that source and cross-checked against the post text. Read our editorial policy →
- Peptime (@ItsPeptime). (2026, May 18). Peptide user survey findings [X post]. x.com/ItsPeptime/status/2056380319331438992 — primary source.
- FormBlends. (2026). 2026 State of Peptides Report. finance.yahoo.com — broader market context.
- Medscape. (2026). Gray Market Peptides: So Much Hype, So Little Data. medscape.com — clinical perspective on gray-market sourcing.
- New York Post. (2026, January 14). Inside the Peptide Gray Market. nypost.com — consumer-press read on the same phenomenon.
Methodology disclaimer: This article summarises publicly shared findings from an independent, self-reported online survey. Numbers reflect selection bias (engaged users), self-report effects, and a single seller-hosted audience. They are not peer-reviewed clinical data and should not be read as evidence of clinical effect.